Kornimate/medical-research-clean huggingface dataset:
evaluating neuromodulation technologies in early recovery

Conditions: Depression; Anxiety; Insomnia

Summary: the study is an open-label comparative effectiveness clinical trial evaluating the impact of three neuromodulation treatment devices to improve the mental health and sobriety status of recovering substance abuse patients. we intend to enroll 200 patients to give us a sufficient number of subjects for the planned comparisons. following informed consent and baseline assessment, patients will be randomly assigned to receive either 1) 15 40-minute sessions of nexalin brain stimulator, a cranial electrical stimulation (ces) device, once-per-day within a 3-week time-frame; 2) 30 20-minute sessions of the fischer wallace stimulator, another ces device, twice-per-day within a 3-week time-frame; 3) 15 40-minute sessions of the david delight, an audio-visual stimulation device (avs), once-per-day within a 3-week time-frame; or 4) the control-group condition of 15 40-minute relaxation therapy sessions once-per-day within a 3-week time-frame. all subjects will then be reassessed at the end of the 3 weeks of treatment and again 1, 3, and 6 months later. in addition to the assigned treatments, all patients will also receive the standard array of services that are provided by behavioral health of the palm beaches (bhopb) including as clinically appropriate, psychiatric medication management and eye movement desensitization response (emdr) therapy. patients diagnosed with post traumatic stress disorder (ptsd) are assessed to determine their suitability for emdr and if suitable, will receive 2 or more emdr sessions. patients without ptsd do not receive emdr therapy.


Eligibility criteria:
inclusion criteria: adults between the ages of 18 and 75 in early recovery from a substance abuse disorder. exclusion criteria: the exclusion criteria are patients diagnosed with 1) an uncontrolled seizure disorder, 2) a psychotic disorder with currently active features (e.g., paranoia), 3) a dissociative identity disorder, 4) a manic episode within the past month, 5) patients with a pace-maker or implanted vagal nerve stimulator, patients prescribed subocone, subutext, \&/or any psychostimulant medication (e.g., alderol, concerta, focalin, metadate, vyvance, etc.) since these medications interfere with the ability of these neuromodulation devices' ability to have the intended effect on patients, and 7) pregnant woman.
tm vs tsv implants loaded early vs conventional in anterior and posterior areas

Conditions: Partial Edentulism; Tooth Disease

Summary: randomized-controlled, multicenter study of trabecular metal (tm) and tapered screw-vent (tsv) dental implants loaded early in maxillary and mandibular sites.

this is a randomized, controlled, multicenter study to assess and compare implant stability of trabecular metal (tm) dental implants and tapered screw-vent (tsv) implants during the early stages of healing i.e. 21 +/- 2 days and 42+/- 2 days, as well as their short term clinical outcomes.

Eligibility criteria:
inclusion criteria: 1. benefit from the implant and restoration 2. provide a voluntarily signed informed consent 3. must be 18 years or older 4. have one or more edentulous area(s) in the posterior maxilla or mandible designated for an implant supported restoration 5. the implantation site must have a functional antagonist to obtain full occlusion. 6. implants adjacent to planned site of implantation should have been in function for at least 1 year. 7. the site intended for implant placement should have healed for at least 4 months from the time of extraction or at least 6 months from any other bone augmentation procedures. 8. the site intended for implant placement should have adequate bone volume to support an implant without the need for augmentation except for minor dehiscence (limited to a vertical height of 2mm), which can be augmented with autogenous bone chips to improve soft tissue attachment. 9. the site intended for implant placement should have residual facial and palatal/lingual plates to be at least 1.0mm thick after implant placement. 10. the site intended for implant placement should have vertical bone volume to extend at least 2.0mm apical to the implant after implant placement. exclusion criteria: 1. subjects mentally incompetent or unable to understand and provide an informed consent 2. smokers, alcoholics or drug abusers 3. subjects with systemic conditions such as uncontrolled diabetes, endocrine disorders, heart disease, immune-compromised subjects or mental disorders 4. use of concurrent medication which inhibits bone metabolism like bisphosphonates, corticosteroids or methotrexate 5. bleeding disorders and/or anticoagulant therapy 6. pregnancy 7. known sensitivity or allergy to any of the implant materials 8. subjects with bruxism or clenching habits 9. uncontrolled periodontal or oral pathologies (e.g. mucosal disease, oral lesions) 10. inadequate oral hygiene 11. history of radiation at the site intended for study implant placement 12. subjects who have previously failed dental implants at the site intended for study implant placement 13. subjects participating in another clinical study 14. subjects who need other surgeries in a site adjacent to the study implant(s) 15. subjects who need other surgeries in a site non-adjacent to the study implant(s) within 6 months of study implant placement

Keywords: dental implants trabecular metal dental implants tsv dental implants zimmer dental implant stability implant stability quotient (isq) resonance frequency analysis (rfa)
iron absorption and utilization in adolescents infected with malaria parasites, hookworms or schistosoma

Conditions: Malaria, Falciparum; Hookworm Infections; Schistosoma Haematobium

Summary: the aim of this study is to investigate the change in iron metabolism in relation to malaria and helminth infections using a stable isotope technique.

the aim of the study is to determine how iron metabolism in subjects with infectious diseases (malaria, hookworm or s. haematobium) differs while infected and after treatment, i.e. the same individuals will be restudied while free of infection.

Eligibility criteria:
inclusion criteria: * children aged 12 to 16 years * body weight \> 30 kg * no chronic medical illnesses * no intake of vitamin/mineral supplements 2 weeks before the study and until the last blood drawing * for each of the 4 arms the respective disease needs to be present (symptomatic malaria, asymptomatic malaria, hookworm infection, s. haematobium infection) without any other concurrent infection exclusion criteria: -

Keywords: iron absorption iron utilization malaria helminth ivory coast acute symptomatic uncomplicated falciparum malaria asymptomatic falciparum malaria moderate to heavy hookworm infection heavy schistosoma haematobium infection
home and locally observed - tracking (halo-trak)

Conditions: Advanced Cancer

Summary: the goal of this observational study is to collect biometric, hrqol, immune response and genomic data continuously and intermittently during and after chemo or immunotherapy for the generation of a complex dataset using a platform which can aggregate different types of data collected over a time period and, to test the potential for analysis within and across data sets with linkage to clinical outcomes. the framework will have capabilities to integrate data from electronic medical records (emrs) such as epic, as well as digital streams including sensor, genomic, imaging and pathology. such a platform can realise the potential for machine learning (ml) methodologies to address important cancer outcomes.

the investigators overarching aim is to determine the relationship between measures of physical performance status including heart rate and steps, health related quality of life (hrqol) and genomic and immunogenomic phenotype on cancer outcomes in patients receiving chemotherapy or immunotherapy for haematological or metastatic cancer including renal (papillary, and rcc), breast, prostate, and other solid tumours. the primary objective is to test the feasibility of integrating diverse data streams (genomic, hr qol and biometric) on a novel platform, capable of integrating data streams thus generating complex datasets for analyses using machine learning methodologies. secondary objectives will be to conduct exploratory analysis assessing the relationship between individual and combined data types and cancer outcomes. analysis using existing and novel computational models will be applied to the data to events in the acute and chronic setting that are common in patients diagnosed with cancer undergoing systemic therapy such as chemotherapy and immunotherapy. the outputs from this study will help inform future studies and trials designed to inform patients about their health status during cancer therapy

Eligibility criteria:
inclusion criteria: * ● a diagnosis of a metastatic or haematological cancer undergoing systemic therapy * undergoing at least 1 planned cycle of chemotherapy or immunotherapy, according to standard of care practices. * ability to understand and the willingness to sign a written informed consent. * able to ambulate without assistance or walking aid. * have an android or ios phone and willing to download the ethera app exclusion criteria: * ● physical disabilities that preclude daily walking * inability to provide informed consent. * unable to use and operate the ethera health monitoring smartphone app. (apple or android) * medical or psychiatric condition which in the investigator's opinion would affect the successful completion of the study.
stem cell study for patients with heart failure

Conditions: Myocardial Ischemia; Congestive Heart Failure; Cardiovascular Disease

Summary: the purpose of this study is to determine if cell therapy with your own cells (autologous cells) delivered with a catheter to regions of the heart with poor blood flow will be safe and if it will improve your ejection fraction and heart failure symptoms.


Eligibility criteria:
inclusion criteria: * subjects greater than 21 years old. * subjects with functional class (nyha) iii ischemic heart failure. * subjects who have attempted "best" cardiac medical therapy including long-acting nitrates, maximal use of beta-adrenergic blocking agents, and angiotensin-converting enzyme inhibitors without control of symptoms. * subjects must be identified as non-candidates for conventional revascularization by their referring cardiologist. the patient's angiogram will then be reviewed by an independent interventional cardiologist and independent cardiac surgeon to determine if the patient is eligible for revascularization. * subjects must have left ventricular ejection fraction \<40% by echocardiography. * all subjects must have a recent coronary angiogram (within the last 1 year) to document the coronary anatomy and insure the presence of coronary disease that is not amenable to standard revascularization procedures. * have serum b-type natriuretic peptide (bnp) level \>100 pg/ml. exclusion criteria: * myocardial infarction (q wave or non-q wave defined as ckmb \>3 times normal) within 30 days of treatment. * successful coronary revascularization procedures within 3 months of study enrollment. * documented stroke or transient ischemic attack (tia) within 60 days of study enrollment. * nyha class i, ii or iv heart failure and patients with idiopathic or non-ischemic heart failure. * history of severe aortic stenosis (aortic valve area \ 2+); severe mitral stenosis (mitral valve area \ 2+). * implantation of biventricular pacemaker within 90 days of study treatment. * severe co-morbidity associated with a reduction in life expectancy of less than 1 year, such as chronic medical illness (i.e. severe chronic obstructive pulmonary disease, renal failure or cancer).

Keywords: heart stem cells low ef heart attack cardiomyopathy congestive heart failure cardiovascular disease heart failure low ejection fraction
assessing the time-course of dexmedetomidine-induced analgesia via eeg

Conditions: Total Hip Arthroplasty (THA); Intrathecal Anesthesia; Hip Osteoarthritis

Summary: objective: to investigate the temporal dynamics of dexmedetomidine's analgesic effects in the brain using eeg. methods: eligible patients scheduled for total hip arthroplasty under intrathecal anesthesia received a continuous infusion of dex at 1.5 μg/(kg·h) for 15 minutes before neuraxial puncture, followed by an additional 15-minute infusion. the study was divided into three phases: phase 1: non-dosing phase (baseline). phase 2: dex preemptive analgesia phase (dex infusion). phase 3: dex cessation phase (post-infusion). outcomes: primary safety outcome: eeg spectral analysis at different phases. secondary outcomes: nrs scores, postoperative nausea and vomiting (ponv), dizziness, agitation, and time to intestinal exhaust within 48 hours. intraoperative hemodynamics were also monitored.

objective: to investigate the temporal dynamics of dexmedetomidine's analgesic effects in the brain using eeg. methods: eligible patients scheduled for total hip arthroplasty under intrathecal anesthesia received a continuous infusion of dex at 1.5 μg/(kg·h) for 15 minutes before neuraxial puncture, followed by an additional 15-minute infusion. the study was divided into three phases: phase 1: non-dosing phase (baseline). phase 2: dex preemptive analgesia phase (dex infusion). phase 3: dex cessation phase (post-infusion). outcomes: primary safety outcome: eeg spectral analysis at different phases. secondary outcomes: nrs scores, postoperative nausea and vomiting (ponv), dizziness, agitation, and time to intestinal exhaust within 48 hours. intraoperative hemodynamic monitoring was performed. eeg/erp monitoring: the 64-site eeg and erp were recorded at different phases

Eligibility criteria:
inclusion criteria: patients with hip osteoarthritis scheduled for total hip arthroplasty under intrathecal anesthesia; age 18-70 years; american society of anesthesiologists (asa) physical status classification i-iii; body mass index (bmi) 22-30 kg/m². exclusion criteria: pre-existing peripheral or central nervous system disorders; mental disorders; cognitive impairment; emergency surgery; or hearing impairment.
changes in serum electrolytes at different glucose concentrations + impact on a non-invasive glucose monitoring method

Conditions: Diabetes Mellitus

Summary: in healthy subjects: continuous monitoring of the glucose concentration in the skin by means of a non-invasive glucose sensor during a glucose clamp when systematically changing the blood glucose concentration (e.g. to hyperglycemia). simultaneous frequent determinations of serum electrolytes.

non-invasive continuous glucose monitoring is a promising approach in diabetes therapy. it is known that changes in glucose concentration in the skin can be registered by means of optical, spectroscopic measures in subjects with diabetes. the precision of such measures, however, so far has been unsatisfactory. this study evaluates the changes in skin glucose concentration by means of a non-invasive glucose sensor and compares these to blood glucose concentrations during a glucose clamp. it is also known that with hyperglycemic blood glucose concentrations there is a consecutive hyponatraemia. this study shall evaluate to which extent and how fast serum electrolyte parameters change when establishing a hyperglycaemic blood glucose level. this shall help estimate which impact these changes in electrolytes have on the non-invasive glucose sensor.

Eligibility criteria:
inclusion criteria: * written informed consent * age between 18 and 65 years exclusion criteria: * uncontrolled hypertension (diastolic blood pressure \> 100 mmhg and/or systolic blood pressure \> 180 mmhg) * pregnancy or lactation period for female subjects * serious clinical signs of a liver disease, acute or chronic hepatitis, acute or chronic kidney disease, or alat \> 2.5 times the upper level of normal values, or serum creatinine \> 1.3 mg/dl (women)/1.5 mg/dl (men) * any serious acute illness (at the decision of the investigator), e.g. sepsis, gastric or duodenal ulcer, acute myocardial infarction, acute asthma attack * any other serious chronic illness (at the decision of the investigator), e.g. chronic obstructive pulmonary disease, any kind of cancer

Keywords: diabetes
mechanism of gastric signet ring cell carcinoma based on microproteomics

Conditions: Gastric Cancer; Signet Ring Cell Carcinoma

Summary: gastric signet ring cell carcinoma (gsrcc) possesses unique epidemiology and pathogenesis in the field of cancer, but its incidence is low. unfortunately, there is currently a lack of systematic research focusing on the prognostic proteomic features of gsrcc. given this knowledge gap, this study aims to comprehensively characterize the proteomic landscape of gsrcc using a reliable and reproducible dia-pct method. this study objectives include characterizing the heterogeneity of gsrcc, performing molecular typing, identifying potential biomarkers and therapeutic targets, and providing a resource for stratified analysis of gsrcc. to achieve these goals, the investigators selected a cohort of 112 gsrcc patients from a pool of over 10,000 gastric cancer patients and conducted a proteomic analysis using the dia-pct method. this meticulous approach revealed four novel proteomic subtypes of gsrcc, each exhibiting unique molecular characteristics. additionally, the investigators discovered that prdx2 and ddx27 can serve as predictive biomarkers for gsrcc, which were further validated in an independent cohort of 75 gsrcc patients. furthermore, the investigators paid particular attention to the mlt-gsrcc subgroup and identified three distinct proteomic clusters among mlt-gsrcc patients. subtype 2 within this subgroup demonstrated the poorest prognosis. through a rigorous screening process, the investigators determined potential targets for the treatment of gsrcc. in conclusion, these findings contribute to the investigators understanding of the heterogeneity of gsrcc and provide valuable resources for future clinical stratification and targeted treatment strategies.


Eligibility criteria:
inclusion criteria: * confirmed gsrcc by pathology, where gsrcc is defined as having a percentage of signet ring cell ≥ 50% * patients with complete medical information * patients with survival follow-up information exclusion criteria: * patients with other malignant tumors * presence of other pathological components (e.g., neuroendocrine carcinoma and squamous cell carcinoma, etc) * incomplete or lost case information

Keywords: gastric signet ring cell carcinoma molecular subtypes proteomics prognostic markers drug target
blending two worlds: traditional aboriginal healing strategies for depression and anxiety

Conditions: Anxiety; Depression

Summary: 1. purpose 1. provide a culturally sensitive and supportive treatment environment for children, youth and families in the aboriginal community experiencing stress, anxiety and depression. 2. gain insight into understanding of the role of traditional healing options provided by aboriginal healers and helpers in the management of stress, anxiety and depression. 3. encourage aboriginal and first nation clients to seek treatment earlier from a culturally supportive system. 2. hypothesis this will be a descriptive hypothesis generating research project, however it is anticipated that members of the aboriginal community experiencing stress, anxiety and depression may experience improved care and outcomes if their treatment includes traditional healing methods. a number of measures of subject and treatment characteristics, stress, anxiety and depression will provide the foundation for triangulation of outcomes in order to describe the impact of the various treatment options (standard care, traditional healing, combined standard care and traditional healing).

aboriginal clients, including first nation youth, may not be confident or comfortable with the standard treatments offered by the current mental health environment. incorporating traditional aboriginal healing methods such as dream work, energy healing, healing circles, pipe ceremonies, self care, smudging, sweat lodge and traditional learning into standard practice will provide a culturally sensitive and supportive environment for children, youth and families experiencing stress, anxiety and depression. it is believed that aboriginal and first nation clients that access treatment options consistent with cultural beliefs will be encouraged to seek treatment earlier and will experience improved care and outcomes. in addition, the improved understanding of the role of traditional healing methods provided by aboriginal healers and helpers in the management of these disorders will help clinicians incorporate these practices in the management of anxiety and depression

Eligibility criteria:
inclusion criteria: * children and adolescents (less than 18 years of age)and families with anxiety and/or depression attending the surrey north child and youth mental health team. exclusion criteria: * subjects with severe anxiety or depression requiring intervention (i.e. hospitalization) or have a past or present history of suicide attempt. subjects with special needs including medical contraindications (i.e. medical conditions including pregnancy), brain injury, developmental disability or fetal alcohol syndrome). those subjects unwilling or unable to participate in a traditional healing options.

Keywords: traditional healing anxiety depression aboriginal children youth